Quantel Medical haalt openbare aanbesteding van Indiaas defensieministerie voor oogheelkundige laserapparatuur binnen
CLERMONT-FERRAND, Frankrijk–(BUSINESS WIRE)– Quantel Medical (Quantel), een internationaal bedrijf in oogheelkundige apparatuur voor de diagnose en behandeling van oogziekten, heeft vandaag bekendgemaakt dat het een opdracht ter waarde van 3 miljoen euro heeft gekregen voor oogheelkundige laserapparatuur.
Krachtens de leveringsovereenkomst met het directoraat-generaal van de medische divisie van het Indiase ministerie van defensie levert Quantel Medical 61 lasers voor fotocoagulatie. De lasers worden ingezet in 53 militaire ziekenhuizen in India. De ‘Supra with Suprascan’ van 532 nanometer is een veelzijdig laserplatform met het vermogen een aantal Multispot- en MicroPulse-patronen te leveren.
Quantel Medical Awarded Tender for Ophthalmic Laser Equipment from India Department of Defense |
|||||
|
CLERMONT-FERRAND, France–(BUSINESS WIRE)– Quantel Medical (Quantel), a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases, announced it has been awarded a €3 million competitive tender for ophthalmic laser equipment. Under the terms of a supply agreement signed by the Directorate General of Armed Forces Medical Services of the Indian Ministry of Defense, Quantel Medical will provide 61 photocoagulator lasers for use in 53 military hospitals across India. The 532nm Supra with Suprascan is a diverse and versatile laser platform capable of delivering a number of Multispot and MicroPulse® patterns. “Diabetes is extremely prevalent in India, affecting more than 62 million individuals, or about 7% of the adult population. It is well known that uncontrolled diabetes can be a precursor for the development of vision-related complications, including diabetic retinopathy and diabetic macular edema, both of which are very common in India. One study suggested that as many as 20% of individuals with diabetes in India are affected by diabetic retinopathy,” said Jean‐Marc Gendre, CEO of Quantel Medical. “This agreement will put an extremely powerful treatment option in the hands of physicians who treat patients with diabetic eye disease. It is a platform that can be adapted to use for other applications as well. Laser treatment of diabetes is in many cases as effective as medical treatment, and it is demonstrated to be much more cost effective,” added Jean‐Marc Gendre, CEO of Quantel Medical. About Quantel Medical Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists. These products are available through direct sales operations in the U.S. and France, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid state lasers for scientific and industrial applications. For more information, please visit www.quantel-medical.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20160329006569/en/ Contacts Quantel Medical |
|||||